What You Ought to Know:
– ConcertAI and NeoGenomics (NASDAQ: NEO) announce a joint software-as-a-service answer in hematological malignancies for analysis analytics, medical trial design, and medical trial operational optimization.
– CTO-H supplies a analysis information answer that’s unprecedented in its scale, longitudinality and biomarker depth. CTO-H is a serious end result of the collaboration jointly announced on Jan. 8, 2024, and the newer joint research completed and scheduled for presentation on the 2024 American Society of Hematology Assembly on Monday, Dec. 9, in San Diego.
NeoGenomics and ConcertAI Introduce CTO-H: Reworking Hematological Malignancy Analysis
In 2023, NeoGenomics and ConcertAI collaborated to redefine analysis options for healthcare suppliers and biopharmaceutical firms addressing the rising variety of new therapeutic entities concentrating on hematological malignancies. Their efforts culminated within the creation of CTO-H, a strong database comprising:
- Over 370,000 affected person lives with detailed medical attributes.
- 7 to 11 years of affected person journey surveillance information.
- Complete biomarker insights, starting from routine assessments to superior genetic variants.
Believed to be the most important reference dataset for hematological malignancies, CTO-H addresses vital challenges in hematological analysis. These embrace:
- Defining consultant populations for early-phase medical trials.
- Making certain management teams align with the evolving remedy paradigms.
- Navigating complexities in late-phase trials, together with competing research and recruitment throughout the focused timeframe.
The remedy panorama for hematological malignancies has developed considerably during the last 5 years, providing more practical choices for sufferers. Nevertheless, this progress has launched challenges in medical analysis, together with heterogeneity in commonplace care, extended remedy durations, and more and more advanced measures of response and residual illness.
“CTO-H represents a pivotal achievement in advancing medical evaluation, research design, and execution planning for hematological malignancies,” mentioned Jeff Elton, PhD, founding CEO of ConcertAI. “Its multi-modal answer delivers unparalleled depth in addressing the complexities of this analysis area.”
Underneath this collaboration:
- ConcertAI will deploy CTO-H by way of its CARAai™ cloud as a SaaS answer.
- NeoGenomics will present biomarker interpretation, specialised testing companies, and professional medical assist to make sure high-confidence analyses and research designs.
At present out there as a pre-release answer, CTO-H will turn into broadly out there on January 17, 2025, promising to raise the precision and effectivity of hematological analysis.
